Page last updated: 2024-09-04

cyc 202 and Vomiting

cyc 202 has been researched along with Vomiting in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armour, S; Chiao, J; Delbaldo, C; Diéras, V; Faivre, S; Frame, S; Gianella-Borradori, A; Girre, V; Green, SR; Laurence, V; Le Tourneau, C; Raymond, E; Vera, K	1

Trials

1 trial(s) available for cyc 202 and Vomiting

Article	Year
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:18 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Maximum Tolerated Dose; Metabolic Diseases; Middle Aged; Nausea; Neoplasms; Purines; Roscovitine; Vomiting	2010

Article

Year

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:18

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Maximum Tolerated Dose; Metabolic Diseases; Middle Aged; Nausea; Neoplasms; Purines; Roscovitine; Vomiting

2010